CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Study Number

501719

Phase

Age Group

Adult

Principal Investigator

Purpose

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Check your eligibility for this trial

Check now

Full Title

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

ClinicalTrials.Gov ID

NCT04269213

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.